A malaria drug may combat tick-borne babesiosis
A malaria drug could help immune-compromised people who can't shake off babesiosis, a tick-borne parasitic infection, a new study says.
Jun 5, 2024
0
1
A malaria drug could help immune-compromised people who can't shake off babesiosis, a tick-borne parasitic infection, a new study says.
Jun 5, 2024
0
1
Researchers have just taken the most fine-grained look to date at inflammatory pain: increased sensitivity to pain that follows an immune response to a wound, infection, sunburn, arthritis, or other trigger.
Jun 5, 2024
0
61
More than 16,000 Australians will be diagnosed with melanoma each year. Most of these will be caught early, and can be cured by surgery.
Jun 5, 2024
0
0
As humans age, hematopoietic stem cells—the immature precursor cells that give rise to all blood and immune cells—accumulate mutations. Some of the mutations allow these stem cells to self-renew and expand more effectively ...
Jun 5, 2024
0
41
A team from the Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine) and Monash University has engineered a COVID-19 vaccine that induced—in pre-clinical models—very long-lasting, protective ...
Jun 4, 2024
0
111
A new study reveals that aging human pancreatic beta cells display features of senescence while maintaining elevated levels of genes crucial for their function. Despite their aging status, these cells therefore exhibit an ...
Jun 4, 2024
0
6
Immunotherapy is based on harnessing a person's own immune system to attack cancer cells. However, patients with certain tumors do not respond to these therapies and it remains unclear why.
Jun 4, 2024
0
33
Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new immunotherapies, only around one in 10 patients ultimately survive.
Jun 4, 2024
0
0
Scientists at Duke-NUS Medical School have identified how the first domino falls after a person encounters an allergen, such as peanuts, shellfish, pollen or dust mites. Their discovery, published in the journal Nature Immunology, ...
Jun 3, 2024
0
46
Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with a manageable safety profile and promising antitumour activity, especially in patients with metastatic cutaneous ...
Jun 3, 2024
0
0